HDM2017

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Phase 1 active Small molecule

At a glance

Generic name	HDM2017
Sponsor	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase 1 Study of HDM2017 in Advanced Solid Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

HDM2017 CI brief — competitive landscape report
HDM2017 updates RSS · CI watch RSS
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. portfolio CI